Simulations Plus

Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call

Retrieved on: 
Montag, Dezember 20, 2021
Data Management, Health, Technology, Software, Pharmaceutical, Biotechnology, Twitter, Drug discovery, Simulations Plus, ESG, Technology, Conference, SLP, Biotechnology, Nasdaq, Research, Investor, Solution, Pharmacokinetics, Webcast, Biophysical environment, Company, Population, Internet, Conference call, Pharmaceutical industry

Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the financial markets on Thursday, January 6, 2022.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the financial markets on Thursday, January 6, 2022.
  • The Company will host a conference call on January 6, 2022, at 5:00 p.m. Eastern Time.
  • All interested parties are invited to join the call by registering here or by calling 1-201-389-0879.
  • The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Conference Calls & Presentations .

Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™

Retrieved on: 
Donnerstag, Dezember 2, 2021
Data Management, Health, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, University, Biophysical environment, Risk, Technology, Private Securities Litigation Reform Act, Company, Hospital, Population, Awareness, Mission statement, ESG, Simulations Plus, Economics, Pharmacokinetics, Solution, Laboratory, SLP, U.S. Securities and Exchange Commission, Software, Nasdaq, Twitter, Research, Biotechnology, Drug discovery, ADMET, Pharmaceutical industry

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its distributor agreement in Japan with Northern Science Consulting for Monolix.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its distributor agreement in Japan with Northern Science Consulting for Monolix.
  • Jonathan Chauvin , President of the Lixoft division, said: We are excited to be partnering with Northern Science Consulting to further serve the needs of the Japanese scientific markets.
  • We are pleased with this agreement as Northern Science Consulting is a well-recognized company in Japan and is already successful in distributing Simulations Plus.
  • Goh Murakami, Chief Executive Officer at Northern Science Consulting Inc., said: Founded in 2004, Northern Science Consulting in Japan strongly supports biological science research and development through the provision and support of software.

Simulations Plus celebrates 25-year anniversary with $25,000 gift to nonprofit Dispensary of Hope

Retrieved on: 
Dienstag, November 30, 2021
Patient, Biophysical environment, Risk, Technology, Association for Accessible Medicines, Private Securities Litigation Reform Act, Company, Population, National Association of Boards of Pharmacy, Mission statement, Health, ESG, Economics, Pharmacokinetics, Prescription, Solution, SLP, National Association, Dangerous Drugs (Supply to Addicts) Regulations 1968, U.S. Securities and Exchange Commission, Software, Twitter, View, Research, Biotechnology, Health equity, Board, Social responsibility, Public health, Simulations Plus, Multimedia, Association, NASDAQ, Drug discovery, Hospital, Management, Pharmaceutical industry

Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, TN.

Key Points: 
  • Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, TN.
  • The group chose Dispensary of Hope because of the strong representation of innovation and improved health outcomes in the pharmaceutical industry.
  • We are pleased to support Dispensary of Hope in their efforts to address this need," said Shawn O'Connor, Chief Executive Officer of Simulations Plus.
  • Dispensary of Hope is committed to providing access to high quality medication for America's most vulnerable (low income and uninsured) with dignity.

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope

Retrieved on: 
Dienstag, November 30, 2021
Technology, Biotechnology, Health, Consulting, Pharmaceutical, Professional Services, Other Philanthropy, Philanthropy, Research, Software, General Health, Fund Raising, Foundation, Science, Patient, Pharmacy, Biophysical environment, CEO, Risk, Technology, Association for Accessible Medicines, Industry, Private Securities Litigation Reform Act, Company, Population, Mission statement, Health, ESG, Simulations Plus, Economics, Pharmacokinetics, Prescription, Solution, SLP, National Association, Dangerous Drugs (Supply to Addicts) Regulations 1968, U.S. Securities and Exchange Commission, Software, Nasdaq, Twitter, Research, Biotechnology, Health equity, Board, Social responsibility, Public health, Association, Drug discovery, Hospital, Pharmaceutical industry, Simulations Plus, Inc., Dispensary of Hope, SIMULATIONS PLUS, INC., DISPENSARY OF HOPE

Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, Tenn.

Key Points: 
  • Dispensary of Hope is a national nonprofit medication distributor headquartered in Nashville, Tenn.
    A team of long-tenured Simulations Plus employees researched and selected recipients aligned with the organization's vision and mission.
  • The group chose Dispensary of Hope because of the strong representation of innovation and improved health outcomes in the pharmaceutical industry.
  • Shawn OConnor, CEO of Simulations Plus, commented: As part of our 25th anniversary, we seek to support other ventures that share our vision of improving health through innovative solutions.
  • Were so grateful to Simulations Plus for this generous gift, added Christopher Palombo, CEO of Dispensary of Hope.

Simulations Plus Names Sharlene Evans to Board of Directors

Retrieved on: 
Freitag, November 19, 2021
Biotechnology, Health, Pharmaceutical, Technology, Software, People, Organization, Biophysical environment, Risk, Audit, Technology, Purdue University, Industrial engineering, Industry, Private Securities Litigation Reform Act, Acquisition, Company, Population, Auburn University, Mission statement, ESG, Simulations Plus, Economics, Pharmacokinetics, Solution, Compensation, SLP, U.S. Securities and Exchange Commission, Software, Nasdaq, Fortune 500, Twitter, Research, SSA, Biotechnology, Board, Hitachi Consulting, Director, Under Secretary of Defense for Acquisition and Sustainment, Multimedia, Drug development, Drug discovery, Management, Risk management

Ms. Evans will replace David L. Ralph, Ph.D. on the Simulations Plus Board of Directors.

Key Points: 
  • Ms. Evans will replace David L. Ralph, Ph.D. on the Simulations Plus Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20211119005238/en/
    Sharlene Evans Joins Simulations Plus Board of Directors (Photo: Business Wire)
    Ms. Evans has a proven track record in executing large-scale improvement projects across complex, multi-site organizations for Fortune 500 clients.
  • As Simulations Plus continues to grow, both organically and through acquisition, attracting, developing, and maintaining top talent will become an increasing priority.
  • Simulations Plus is a great company, with strong leadership serving world-class customers and providing tangible value.

Simulations Plus Presented Breakthrough Scientific Data at Top Liver Disease Conference

Retrieved on: 
Donnerstag, November 18, 2021
Biotechnology, Health, Pharmaceutical, Technology, Software, Patient, Institute of Liver and Biliary Sciences, Biophysical environment, Principal, CSO, Risk, Technology, Private Securities Litigation Reform Act, Company, American Association of Clinical Endocrinologists, Population, Mission statement, Fatty liver disease, Diet, ESG, Simulations Plus, Clinical trial, Economics, Human, Pharmacokinetics, Solution, SLP, Weight loss, Immunology, U.S. Securities and Exchange Commission, Software, Nasdaq, Twitter, Research, Biotechnology, NASH, American Association, Fibrosis, Association, Drug discovery, Pharmaceutical industry

Lisl Shoda , Director of Immunology and Principal Scientist from Simulations Plus, presented Yo-Yo Dieting Predicted to Contribute to Fibrosis Score Reductions in Untreated (Placebo) Cohorts at The Liver Meeting , the American Association for the Study of Liver Diseases annual conference.

Key Points: 
  • Lisl Shoda , Director of Immunology and Principal Scientist from Simulations Plus, presented Yo-Yo Dieting Predicted to Contribute to Fibrosis Score Reductions in Untreated (Placebo) Cohorts at The Liver Meeting , the American Association for the Study of Liver Diseases annual conference.
  • Scott Q Siler , CSO of the DILIsym Services division of Simulations Plus, said: We have known for many years that weight loss provides improvement in many aspects of NASH, including fibrosis.
  • Reducing the placebo response and attrition rates of these candidate treatments can get them to patients who need them.
  • Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

Simulations Plus Releases RENAsym® Version 1A Software for Kidney Injury

Retrieved on: 
Dienstag, November 16, 2021
Health, Technology, Software, Clinical Trials, Pharmaceutical, Biotechnology, Population, Biomarker, 1A, Private Securities Litigation Reform Act, SLP, SBIR, Economics, Acute kidney injury, U.S. Securities and Exchange Commission, Kidney, Simulations Plus, National, Technology, Risk, Mission statement, Research, Software, Biophysical environment, QST, Human, Twitter, Biotechnology, Company, ESG, Solution, Therapy, Drug discovery, Digestive, Pharmacokinetics, Nasdaq, Patient, FDA, Drug development, Pharmaceutical industry, Medical device

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services division has released RENAsym version 1A, the first version of its novel quantitative systems toxicology (QST) software for predicting and investigating drug-induced kidney injury.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services division has released RENAsym version 1A, the first version of its novel quantitative systems toxicology (QST) software for predicting and investigating drug-induced kidney injury.
  • RENAsym, our newest QST platform, will allow us to help companies developing new therapeutics understand and avoid potential kidney injury issues as well, thereby expanding the reach of our software and associated consulting services into an important area.
  • Dr. Jeffrey Woodhead , Principal Scientist and lead on the RENAsym program, added: RENAsym includes various mechanisms by which therapeutics can injure the kidneys of preclinical species and humans, as well as important biomarkers of kidney injury and function.
  • RENAsym modeling supports key drug development decisions by predicting potential kidney injury risk of new drug candidates.

Simulations Plus Releases GastroPlus® Version 9.8.2

Retrieved on: 
Donnerstag, Oktober 28, 2021
Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, Science, Research, Biotechnology, Technology, Biophysical environment, Industry, Twitter, Private Securities Litigation Reform Act, Simulations Plus, Biopharmaceutical, Drug discovery, ESG, U.S. Securities and Exchange Commission, Learning, Software, Company, Economics, Pharmacokinetics, PBPK, Solution, Nasdaq, Mission statement, Risk, Population, SLP, Medical device

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced the release of version 9.8.2 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling program, GastroPlus .

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced the release of version 9.8.2 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling program, GastroPlus .
  • For 25 years, Simulations Plus has remained committed to developing and improving state-of-the-art software tools, educating scientists worldwide with the best and most innovative science, and advancing in silico modeling and simulation.
  • Key enhancements in GastroPlus version 9.8.2 include:
    Dr. Viera Lukacova , Chief Scientist, said: PBBM/PBPK modeling and simulation is both an art and a science.
  • John DiBella, Simulations Plus Division President, added: All the feature enhancements offered in this new version of GastroPlus are the result of the ongoing dialog and input from the GastroPlus User Group, requests from our customers, and the shared learnings from our collaborations with regulatory agencies and industry partners globally.

Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products

Retrieved on: 
Dienstag, Oktober 26, 2021
University, Biotechnology, Education, Technology, FDA, Health, Pharmaceutical, Other Science, Software, Science, Clinical Trials, Science, LAI, Research, Biotechnology, Technology, University, Biophysical environment, Outline, Government, Contract, Industry, Human services, Name, Nanoparticle, Drug development, Twitter, Partnership, Pharmacy, Patient, Simulations Plus, Trustee, FDA, Biopharmaceutical, Liposome, Drug discovery, Food, ESG, U.S. Securities and Exchange Commission, Administration, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, United States Department of Health and Human Services, Software, Food and Drug Administration, Company, Economics, Private Securities Litigation Reform Act, Independent agencies of the United States government, IVIVC, Program, PBPK, Pharmacokinetics, Solution, Nasdaq, Mission statement, Pharmaceutics, Â, Emulsion, Risk, Population, SLP, Department, Pharmaceutical industry, Medical device, the Burgess laboratory in the Department of Pharmaceutical Sciences at the University of Connecticut, Simulations Plus, Inc., THE BURGESS LABORATORY IN THE DEPARTMENT OF PHARMACEUTICAL SCIENCES AT THE UNIVERSITY OF CONNECTICUT, SIMULATIONS PLUS, INC.

Dr. Viera Lukacova , Chief Scientist at Simulations Plus, said: Our pioneering PBBM/PBPK modeling approaches in GastroPlus for LAI products were kickstarted by an FDA-funded grant award in 2015.

Key Points: 
  • Dr. Viera Lukacova , Chief Scientist at Simulations Plus, said: Our pioneering PBBM/PBPK modeling approaches in GastroPlus for LAI products were kickstarted by an FDA-funded grant award in 2015.
  • This partnership with Dr. Burgess and her team will extend and enhance our current state-of-the-art models to address many client requests.
  • FDA scientific and program staff will actively collaborate with the University of Connecticut and Simulations Plus.
  • We are excited about the funding of this FDA contract that allows us to collaborate with Simulations Plus, said Dr. Burgess.

Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results

Retrieved on: 
Montag, Oktober 25, 2021
Biotechnology, Health, Pharmaceutical, Technology, Software, ADMET, Research, Biotechnology, Technology, Biophysical environment, Conference call, Twitter, Private Securities Litigation Reform Act, Simulations Plus, Drug discovery, Investor, Machine learning, ESG, U.S. Securities and Exchange Commission, Conference, Internet, Software, Company, Webcast, Economics, Board, CAGR, Pharmacokinetics, Solution, Nasdaq, Mission statement, Acquisition, Risk, Population, SLP, Director, Risk management, Video game

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today reported financial results for its fourth quarter and full year 2021 fiscal year, ended August 31, 2021.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today reported financial results for its fourth quarter and full year 2021 fiscal year, ended August 31, 2021.
  • Services revenue is expected to recover sequentially throughout fiscal 2022 and any acquisitions would be incremental to the revenue growth target above.
  • The Company will host a conference call on October 25, 2021, at 5 p.m. Eastern Time.
  • Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.